Nanobiotix S.A. (NBTX) is a Paris- and Cambridge, Massachusetts-based late-clinical-stage biotechnology company developing physics-based nanomedicine for cancer. Its lead asset, hafnium oxide nanoparticle radioenhancer NBTXR3 — licensed to Johnson & Johnson as JNJ-1900 — is designed to amplify the effect of radiotherapy inside tumor tissue.
The sponsored ADRs traded at $28.61 in the opening minutes of Thursday's session, up $1.71 or 6.36%, against Wednesday's close of $26.90. The direction was decisively higher, with the stock bid as high as $29.07 before the opening bell. No verified company-specific catalyst explained the gain; the move is best characterized as a sharp bounce inside an already volatile, thinly traded name.
No verified news or fundamental catalyst found. Nanobiotix has not issued a press release since a routine Nov. 12 disclosure of voting rights and share capital, and its only substantive November release was a Nov. 9 notice of participation in the Jefferies and UBS healthcare conferences in London on Nov. 16 and 17 — an agenda item, not a strategic announcement. Those presentations did not stem the prior decline.
The bounce is more consistent with a technical snapback than with new information. The stock had fallen in five straight sessions, sliding from $32.95 on Nov. 11 to $26.90 on Nov. 18, a decline of about 18% that pushed it well under its 20-day, 50-day and 200-day moving averages. With a float of roughly 35 million shares and daily turnover often in the tens of thousands of shares, price discovery in the name is shallow, and short-covering or a handful of larger buy orders can move the quote several percentage points without any change in the fundamental story. An opening gap higher and immediate buying in the first minutes is a pattern typical of speculative micro-cap flow rather than institutional accumulation.
Turnover has been running below normal. Wednesday's session saw roughly 44,000 shares change hands against a 20-day average near 148,000, and early Thursday volume was modest, so the advance rests on limited participation and could prove fragile.
The move did not track the broader tape closely. Nanobiotix traded lower earlier in the week during a wider pullback in technology and healthcare growth names, and Thursday's rebound came without a matching catalyst in oncology peers or biotech exchange-traded funds, reinforcing the technical explanation.
On the chart, $28.61 leaves the shares below immediate resistance formed by the 50-day average around $29.72 and a prior swing area near €30.36 on the Paris listing. Last week's breakdown below $28.21 was the trigger for the selling; Thursday's recovery puts the stock back at that level. Support remains far below, in the high teens.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event lands at 12 out of 100. The news component is close to zero: there was no release, filing, trial update, financing, or rating action on the day, only residual interest in an investor conference schedule. The price component is also weak. Over the prior 60 sessions the shares averaged an absolute daily move of about 4.1%, so today's 6.36% was only around 1.6 times normal. Fifteen of those 60 sessions produced moves of equal or larger size. A routine swing plus absent news produces a low score.
The next hard datapoint is likely to be the company's full-year 2026 results, expected in the first quarter, following first-half revenue of €3.6 million and a net loss of €34.3 million reported Sept. 24. Investors will revisit that report's central message: €110.9 million in cash, which management says funds operations into 2029.
Clinical and partnership news is the bigger swing factor. The Phase 1 melanoma dataset presented at ESMO in late October showed a 41.7% overall response rate and a median overall survival of 17.8 months in anti-PD-1-resistant patients, and any expansion of that program, or a milestone disclosure from Johnson & Johnson, would carry far more weight than daily price action. Analyst consensus remains constructive — a Moderate Buy with an average target well above the current price — but ratings have not moved the tape recently.
Risks are familiar for a clinical-stage biotech: trial timing, regulatory decisions, dilution, and the dependence of the equity story on a single partnered asset. Sector sentiment toward higher-risk healthcare names remains uneven.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions are gathered in its curated Trending AI Robots section. The bots differ widely in strategy, holding period, performance metrics, and the symbols they trade, so the list is a practical starting point for comparing approaches side by side. Readers looking to pair systematic strategies with their own research can review the featured robots and evaluate which style fits their objectives.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
The 10-day RSI Indicator for NBTX moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 instances where the indicator moved out of the overbought zone. In 25 of the 29 cases the stock moved lower in the days that followed. This puts the odds of a move down at 86%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBTX as a result. In 82 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for NBTX turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 34 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
NBTX moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for NBTX moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
NBTX broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for NBTX crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +2.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBTX advanced for three days, in 188 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 151 of 188 cases where NBTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-46.722) is normal, around the industry mean (3.596). P/E Ratio (-28.101) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (48.077) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. NBTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology